Pharmacology PhD Program
As defined by the American Society for Experimental Therapeutics, “Pharmacology is the science of how drugs act on biological systems and how the body responds to the drug.
The study of pharmacology encompasses the sources, chemical properties, biological effects, and therapeutic uses of drugs. Pharmacy uses the knowledge derived from pharmacology to achieve optimal therapeutic outcomes through the appropriate preparation and dispensing of medicines.
Pharmacology integrates the knowledge of many disciplines, including medicine, pharmacy, dentistry, nursing, and veterinary medicine. This integrative nature allows pharmacology to make unique and significant contributions to human health.”
Michigan Pharmacology faculty, trainees, and research staff focus their work on understanding the complexity of cellular processes and the disease states can that occur when things go wrong. Some Pharmacology laboratories concentrate on elucidating how information is transmitted to cells in response to ligand binding to cell-surface receptors. Other laboratories work on molecular and genetic mechanisms responsible for disease, addiction, and reward. Still others investigate the actions of novel therapeutics in whole animals and in humans. State-of-the art techniques include induced pluripotent stem cell models, transgenic mouse, rabbit, and zebrafish models, high resolution imaging coupled to electrophysiology, and RNA therapeutics. Key collaborations with physicians provide access to patient samples and clinical trials.
The job market for pharmacology graduates is excellent. Career opportunities exist in the academe, the pharmaceutical industry, the burgeoning biotech industry, and government agencies. Importantly, many member of our extensive alumni base serve as career mentors and advisors to our trainees, opening doors and providing key contacts.
To learn more about where our PhD students go after graduation, see the Rackham Graduate School Program Statistics.
PIBS Funding
Doctoral students receive funding, which includes full tuition, healthcare benefits, and a stipend. The first year of funding comes directly from PIBS. Then Pharmacology coordinates funding through graduation from a wide variety of sources.
Many second year students are appointed to institutional T32 training grants, including the Pharmacological Sciences Training Program (PSTP), Systems and Integrative Biology (SIB), and the Human Genetics Training Grant. It is also common for senior students to secure individual fellowships after writing an F31 proposal in Pharmacology 502 - Introduction to Scientific Communication.
Recent Alumni
2025
- Elyse Frydendall, PhD, Consultant, Boston Consulting Group
Thesis: “Human Cytochrome P450 Enzymes in Drug and Fatty Acid Metabolism”
Advisor: Emily Scott, PhD - Livia Stanger, PhD, Consultant, Boston Consulting Group
Thesis: "Antithrombotic Therapies: Targeting Novel Approaches to Improve the treatment of Cardiovascular Disease”
Advisor: Mike Holinstat, PhD - Nathalie Momplaisir, PhD, Postdoctoral Fellowship, Abbvie
Thesis: "Decoding Gai/o Signaling Networks”
Advisor: Alan Smrcka, PhD - James Teuber, PhD, Postdoctoral Researcher at UT Southwestern Medical Center
Thesis: "Regulatory Functions of RAC1 Palmitoylation in Cardiac Hypertrophy and Cardiomyocyte Signaling”
Advisor: Matt Brody, PhD
2024
- Gwen Burgess, PhD, Postdoctoral Fellowship, Penn State University
Thesis: "Behavioral Effects of MOR Agonists in the Presence or Absence of Chronic Neuropathic Pain"
Advisor: Emily Jutkiewicz, PhD - Juan Valentin-Goyco, PhD, Sr. Scientist, Genentech
Thesis: "Mechanistic and Pharmacological Studies of 11β-hydroxylase (P450 11B1) and Aldosterone Synthase (P450 11B2)”
Advisor: Richard Auchus, MD, PhD - Robert Goldsmith, PhD, Engagement Manager, Complete HEOR Solutions
Thesis: “Characterizing the Role of Palmitoylation in Cardiac Fibroblast Activation and Fibrosis”
Advisor: Matt Brody, PhD - Liz Jaeckel, PhD, Postdoctoral Research Associate, Broad Institute of MIT and Harvard
Thesis: “Effects of Chronic Morphine Treatment on Pre- and Postsynaptic Thalamo-Cortico-Striatal Mu Opioid Receptor Signaling”
Advisor: William Birdsong, PhD - Anne Lietzke, PhD, Lead Scientist, Business Development Manager, Gnome Sciences
Thesis: ”Limitations in mitochondrial programming restrain the maturation of human stem cell-derived β cells”
Advisor: Scott Soleimanpour, MD & Les Satin, PhD